Signadori Bio is a preclinical-stage biopharmaceutical company developing a next generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform to treat solid tumors
Signadori Bio is a preclinical-stage biopharmaceutical company developing a next generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform to treat solid tumors.